- Voyageur Pharmaceuticals (TSXV:VM) has announced a strategic partnership with a pharmaceutical company in Central America
- This officially kickstarts the company’s entry into the global market
- The partnership will unveil the company’s suite of five Health Canada-licensed barium contrast products in the first half of 2024
- Shares of Voyageur Pharmaceuticals are up 25 per cent to C$0.05 as of 12:31 pm ET
Voyageur Pharmaceuticals (TSXV:VM) has revealed a strategic partnership with a pharmaceutical company in Central America, officially kickstarting the company’s entry into the global market.
In a news release, the Calgary-based company stated on Thursday that the partnership will unveil its suite of five Health Canada-licensed barium contrast products in the first half of 2024.
These products, Voyaguer Pharmaceuticals said, are pivotal in diagnosing diseases, disorders and abnormalities within the digestive system. They can also be integrated with K-ray and computed tomography (CT scan) procedures.
“We are in active discussions with multiple distributors and clients both domestically and internationally in preparation for our imminent product launch,” Brent Willis, CEO of Voyageur Pharmaceuticals, said in a statement. “Concurrently, we are meticulously advancing the formulation and rigorous testing of our full suite of products, prioritizing quality and efficacy.“
Voyageur Pharmaceuticals is focused on developing barium, iodine and carbon active pharmaceutical ingredients and high-performance, cost-effective imaging contrast agents.
Shares of Voyageur Pharmaceuticals are up 25 per cent to C$0.05 as of 12:31 pm ET.
Join the discussion: Find out what everybody’s saying about this stock on the Voyageur Pharmaceuticals Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.